Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within 1 month of diagnosis since 1965 were reviewed: 1148 chronic phase (CP), 175 accelerated phase (AP), and 246 blastic phase (BP). The median survival was 8.9 years in CP, 4.8 years in AP, and 6 months in BP...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Kantarjian, Hagop, O'Brien, Susan, Jabbour, Elias, Garcia-Manero, Guillermo, Quintas-Cardama, Alfonso, Shan, Jenny, Rios, Mary Beth, Ravandi, Farhad, Faderl, Stefan, Kadia, Tapan, Borthakur, Gautam, Huang, Xuelin, Champlin, Richard, Talpaz, Moshe, Cortes, Jorge
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2012
נושאים:
Clinical Trials and Observations
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3311242/
https://ncbi.nlm.nih.gov/pubmed/22228624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-08-358135
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים